

01/15/04 12:01 FAX

DB&R PHILA.

003

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims

1. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound consisting of the formula X_1 -SEQ ID NO:1- X_2 wherein
 - X_1 is from zero to twelve amino acids, and
 - X_2 is from zero to twelve amino acids.
2. (Original) The composition of Claim 1, wherein
 - X_1 is from zero to six amino acids, and
 - X_2 is from zero to six amino acids
3. (Original) The composition of claim 1 wherein
 - X_1 is
 - (i) zero amino acids, or
 - (ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and
 - X_2 is
 - (i) zero amino acids, or
 - (ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.
4. (Original) The composition of claim 1 wherein the compound has substantial amino acid sequence homology to the amino acid sequence SEQ ID NO:4.
5. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:1.

PHIP365641\1

- 2 -

01/15/04 12:01 FAX

DB&R PHILA.

004

6. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:9.

7. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:10.

- 8. Cancelled
- 9. Cancelled
- 10. Cancelled
- 11. Cancelled
- 12. Cancelled
- 13. Cancelled
- 14. Cancelled
- 15. Cancelled
- 16. Cancelled
- 17. Cancelled
- 18. Cancelled
- 19. Cancelled
- 20. Cancelled
- 21. Cancelled
- 22. Cancelled
- 23. Cancelled

24. (Original) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a composition according to claim 1.

- 25. Cancelled
- 26. Cancelled
- 27. Cancelled
- 28. Cancelled
- 29. Cancelled
- 30. Cancelled

PHIP365641\1

- 3 -

01/15/04 12:02 FAX

DB&R PHILA.

005

31. Cancelled
32. Cancelled
33. Cancelled
34. Cancelled
35. Cancelled
36. Cancelled
37. Cancelled
38. Cancelled
39. Cancelled
40. Cancelled
41. Cancelled
42. Cancelled
43. Cancelled
44. Cancelled
45. Cancelled
46. Cancelled
47. Cancelled
48. Cancelled

49. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 2.

50. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 3.

51. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 4.

PHDP365641V1

- 4 -

01/15/04 12:02 FAX

DB&R PHILA.

006

52. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 5.

53. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 6.

54. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 7.

55. (Previously presented) A method for inhibiting angiogenesis comprising administering to a mammal an effective amount of a compound of the formula X_1 -SEQ ID NO:1- X_2 wherein

X_1 is from zero to twelve amino acids, and

X_2 is from zero to twelve amino acids.

56. (Currently Amended) A method of inhibiting angiogenesis according to claim 1 ~~55~~ wherein

X_1 is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

X_2 is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.

PHIP3656411

- 5 -